Breakthrough- Product Innovation of the three paths.docVIP

 PAGE \* MERGEFORMAT 5 ‘Breakthrough’: Product Innovation of the three paths Many people have such a misunderstanding: We are a weak foundation, costs are low, can not do product development and product innovation. In fact, this is a misinterpretation of the product innovation. Marketing system in force in the core, we believe that the pharmaceutical industry’s R amp;amp; D / Innovation is divided into three types. First, based on the technical level of product innovation, that is, original new drugs. By Pfizer, for example, from the birth in 1849 onwards, in order to de-worming medicine ‘Tower Hill Road, Sugar-year’ started, and then to citric acid, penicillin, oxytetracycline, but also through self-development, product acquisitions, access to Lipitor, Luohuo xi, Zoloft and other products. R amp;amp; D reports that Pfizer’s clinical-stage product line, the follow-up there were as many as 60 drugs. But, most of China’s pharmaceutical companies, doing original new drugs, there are several major barriers: lack of funds is determined enough, no clear objectives and the foundation is not strong, configuration incomplete. At present only a few enterprises have the capacity to conduct R amp;amp; D-driven strategy, the precursor to chemical drugs in medicine, pharmaceutical, and veteran Hengrui strength pharmaceutical companies, etc.; traditional Chinese medicine in Hong edge Wanxi, Tasly, divinity and so on. However, if we select from the thousands of paintings in the ‘Mona Lisa’, but also need to: clarify the strategy of the market, unimpeded financing channels, to determine research and development model, integrating global resources, improve the means of intellectual property protection. Second, based on competitive levels of innovation, namely, follow-up record of fake drugs. The essence of this strategy is to do ‘parody’ started, but to achieve beyond. Must ‘ME-TOO’, must ‘ME-BETTER’. Panasonic pursues a ‘improvements are not only invented’ principle a